TriangleCADI-05 + Pembrolizumab (NCT07455032)
CADI-05 + Pembrolizumab trial for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07455032). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with locally advanced head and neck squamous cell carcinoma that can be removed with surgery.
The idea: before surgery, add CADI-05, an experimental biologic injected into the skin, to the immunotherapy pembrolizumab, given by vein. CADI-05 is given weekly for five weeks.
This phase 1 study plans 22 patients and looks at dose limiting side effects. At Fox Chase Cancer Center in Philadelphia, Parth Desai leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.